Skip to main content

Tm Biosciences Closes $CA12M Private Placement

NEW YORK, Dec. 22 (GenomeWeb News) - Tm Biosciences of Toronto said today it had closed a $CA12 million ($9 million) private placement

 

In this placement, the publicly traded company sold 37.5 million shares at $CA.32 per unit, which includes a common share in the capital of the company and a purchase warrant for a half of a common share that can be exercised at the price of $CA.40 per share through June 2005. The $CA12 million figure represented the gross proceeds.

 

The company said the financing would be used for further development and commercialization of the company's genetic tests, which are based on its Tm 100 platform.

 

The company recently received a $CA 7.3 million investment from Technology Partnerships Canada, a Canadian government funding agency.

 

"The proceeds of this financing, together with the recently announced $7.3 million investment from Technology Partnerships Canada (TPC), provide Tm with the financial security to move into profitability," Greg Hines, President and CEO of Tm Bioscience, said in a statement.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.